EUVIMEDEUVIMED entdecken
Crossref

The Effects of 5 Years of Growth Hormone Treatment on Growth and Body Composition in Patients with Temple Syndrome

Alicia F Juriaans, Demi J Trueba-Timmermans, Gerthe F Kerkhof, Lionne N Grootjen, Sylvia Walet, Theo C J Sas, Joost Rotteveel, Nitash Zwaveling-Soonawala, Annemarie A Verrijn Stuart, Anita C S Hokken-Koelega

Hormone Research in Paediatrics · 2023

DOI: 10.1159/000530420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone Research in Paediatrics, 2023. Verfasst von Alicia F Juriaans und 9 weiteren Autor:innen. Beteiligte Einrichtung: Dutch Reference Center for Prader-Willi Syndrome/Prader-Willi-like, Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Human Growth Hormone, Prader-Willi Syndrome. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Temple syndrome (TS14) is a rare imprinting disorder caused by maternal uniparental disomy of chromosome 14, paternal deletion of 14q32.2, or an isolated methylation defect. Most patients with TS14 develop precocious puberty. Some patients with TS14 are treated with growth hormone (GH). However, evidence for the effectiveness of GH treatment in patients with TS14 is limited.

Methods

This study describes the effect of GH treatment in 13 children and provides a subgroup analysis of 5 prepubertal children with TS14. We studied height, weight, body composition by dual-energy X-ray absorptiometry, resting energy expenditure (REE), and laboratory parameters during 5 years of GH treatment.

Results

In the entire group, mean (95% CI) height SDS increased significantly during 5 years of GH treatment from −1.78 (−2.52; −1.04) to 0.11 (−0.66; 0.87). Fat mass percentage SDS decreased significantly during the first year of GH, and lean body mass (LBM) SDS and LBM index increased significantly during 5 years of treatment. IGF-1 and IGF-BP3 levels rose rapidly during GH treatment, and the IGF-1/IGF-BP3 molar ratio remained relatively low. Thyroid hormone levels, fasting serum glucose, and insulin levels remained normal. In the prepubertal group, median (interquartile range [IQR]) height SDS, LBM SDS, and LBM index also increased. REE was normal at start and did not change during 1 year of treatment. Five patients reached adult height and their median (IQR) height SDS was 0.67 (−1.83; −0.01).

Conclusion

GH treatment in patients with TS14 normalizes height SDS and improves body composition. There were no adverse effects or safety concerns during GH treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormonePrader-Willi SyndromeAdultChildHumansGrowth HormoneFaciesImprinting DisordersUniparental DisomyBody HeightInsulin-Like Growth Factor IBody CompositionMuscle Hypotonia

Stichwörter der Autor:innen

Growth hormone treatmentPrader-Willi-like phenotypeSilver-Russell spectrum disorderTemple syndrome

Substanzen

Insulin-Like Growth Factor IHuman Growth HormoneGrowth Hormone

Autor:innen und Institutionen

  • Dutch Reference Center for Prader-Willi Syndrome/Prader-Willi-like, Rotterdam, The Netherlands.
  • Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children's Hospital, Rotterdam, The Netherlands.
  • Dutch Growth Research Foundation, Rotterdam, The Netherlands.
  • Diabeter, Center for Pediatric and Adult Diabetes Care and Research, Rotterdam, The Netherlands.
  • Department of Pediatric Endocrinology, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Department of Pediatrics, Subdivision of Endocrinology, Wilhelmina Children's Hospital, Utrecht University Medical Center, Utrecht, The Netherlands.

Zitieren

APA

Juriaans, A. F., Trueba-Timmermans, D. J., Kerkhof, G. F., Grootjen, L. N., Walet, S., Sas, T. C. J., Rotteveel, J., Zwaveling-Soonawala, N., Verrijn Stuart, A. A., & Hokken-Koelega, A. C. S. (2023). The Effects of 5 Years of Growth Hormone Treatment on Growth and Body Composition in Patients with Temple Syndrome. Hormone Research in Paediatrics. https://doi.org/10.1159/000530420

Vancouver

Juriaans AF, Trueba-Timmermans DJ, Kerkhof GF, Grootjen LN, Walet S, Sas TCJ, et al. The Effects of 5 Years of Growth Hormone Treatment on Growth and Body Composition in Patients with Temple Syndrome. Hormone Research in Paediatrics. 2023. doi:10.1159/000530420

BibTeX
@article{Juriaans2023,
  author = {Juriaans, Alicia F and Trueba-Timmermans, Demi J and Kerkhof, Gerthe F and Grootjen, Lionne N and Walet, Sylvia and Sas, Theo C J and Rotteveel, Joost and Zwaveling-Soonawala, Nitash and Verrijn Stuart, Annemarie A and Hokken-Koelega, Anita C S},
  title = {The Effects of 5 Years of Growth Hormone Treatment on Growth and Body Composition in Patients with Temple Syndrome},
  journal = {Hormone Research in Paediatrics},
  year = {2023},
  doi = {10.1159/000530420}
}
Kostenlos starten →